Follow
Adil Daud
Adil Daud
Verified email at ucsf.edu - Homepage
Title
Cited by
Cited by
Year
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
57742015
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
New England Journal of Medicine 369 (2), 134-144, 2013
41652013
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ...
New England Journal of Medicine 367 (18), 1694-1703, 2012
30742012
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ...
The Lancet 384 (9948), 1109-1117, 2014
20762014
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
17442015
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet 390 (10105), 1853-1862, 2017
12602017
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ...
New England Journal of Medicine 374 (26), 2542-2552, 2016
12562016
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity
ML Broz, M Binnewies, B Boldajipour, AE Nelson, JL Pollack, DJ Erle, ...
Cancer cell 26 (5), 638-652, 2014
11552014
Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ...
Jama 315 (15), 1600-1609, 2016
10862016
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet Oncology 20 (9), 1239-1251, 2019
9922019
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
AI Daud, RC DeConti, S Andrews, P Urbas, AI Riker, VK Sondak, ...
Journal of clinical oncology 26 (36), 5896, 2008
8412008
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
KC Barry, J Hsu, ML Broz, FJ Cueto, M Binnewies, AJ Combes, ...
Nature medicine 24 (8), 1178-1191, 2018
7822018
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
Annals of Oncology 30 (4), 582-588, 2019
7792019
Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors
A Patnaik, SP Kang, D Rasco, KP Papadopoulos, J Elassaiss-Schaap, ...
Clinical cancer research 21 (19), 4286-4293, 2015
7642015
Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12
CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ...
Immunity 49 (6), 1148-1161. e7, 2018
7482018
Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab
FS Hodi, WJ Hwu, R Kefford, JS Weber, A Daud, O Hamid, A Patnaik, ...
Journal of Clinical Oncology 34 (13), 1510, 2016
7312016
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable …
A Hauschild, SS Agarwala, U Trefzer, D Hogg, C Robert, P Hersey, ...
6872007
Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma
AI Daud, JD Wolchok, C Robert, WJ Hwu, JS Weber, A Ribas, FS Hodi, ...
Journal of Clinical Oncology 34 (34), 4102, 2016
6182016
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ...
Clinical cancer research 8 (8), 2505-2511, 2002
6112002
KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
N Engl J Med 372 (26), 2521-2532, 2015
5912015
The system can't perform the operation now. Try again later.
Articles 1–20